RUNX2 mutations do not necessarily lead to the clinical symptoms of CCD; therefore, it is essential to calculate the mutation rate of RUNX2. A study by Tomimatsu et al. verified that the mRNA level of RUNX2 in patients decreased by 75.5 %, and significant CCD symptoms occurred [12]. Here, RUNX2 is linked to cleidocranial dysplasia 1.